Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0020437 (
hypercalcemia
)
10,293
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Evidence has been presented for prostaglandin-mediated
hypercalcemia
and bone resorption in malignancies of both, experimental animals and man. Occurence of
hypercalcemia
in cancer patients is known for a long time, but its pathogenesis has been poorly understood so far. Besides ectopic parathyroid hormone secretion by tumors, an osteoclast-activating factor released from leukocytes and direct bone destruction by
tumor
cells, prostaglandins of the E series have to be considered as one of the candicates involved in the pathomechanism of
hypercalcemia
and osteoclastic osteolysis in cancer patients. This new concept on the pathophysiology of cancer-associated
hypercalcemia
has implications for the diagnosis and management of this common complication of
neoplastic disease
.
...
PMID:Prostaglandin-mediated hypercalcemia: a paraneoplastic syndrome. 20 5
Two patients with Burkitt's lymphoma presented with severe
hypercalcemia
, a previously unreported complication of this
tumor
. Roentgenograms and radionuclide scans showed multiple osteolytic lesions in both patients. Plasma parathyroid hormone (PTH) was undetectable during the
hypercalcemia
phase. Chemotherapy was followed by rapid
tumor
lysis, hyperphosphatemia, phosphaturia and hypocalcemia. The hypocalcemic phase persisted for two weeks despite rapid normalization of serum phosphorus and renal function. Measurement of urinary cyclic AMP, an index of PTH action, indicated that parathyroid function had been suppressed by the
hypercalcemia
and remained suppressed for almost one week despite marked hypocalcemia.
...
PMID:Hypercalcemia with suppressed parathyroid hormone in Burkitt's lymphoma. 20 38
Au autopsy case of cholangiocarcinoma which showed clinically
hypercalcemia
and hypophosphatemia without bone metastases is presented in this report. Although parathyroid hormone (PTH)-like substance of 520 ng/g. dry weight was measured in neoplastic tissue by the radioimmunoassay, membrane-limited secretory granules as those of parathyroid gland were not found in the fine structure. The significance of an existence of secretory granules in ectopic PTH producing
tumor
is discussed.
...
PMID:An autopsy case of cholangiocarcinoma with hypercalcemia. 21 Jun 21
Prostaglandin E concentrations were measured in a patiet with breast carcinoma,
hypercalcemia
, undetectable parathyroid hormone (PTH) and no evidence of bone metastases. Catheterization of the drainage bed of her
tumor
documented production of E series prostaglandins. Treatment with the largest recommended doses of indomethacin for 10 days failed to lower her plasma prostaglandin E (PGE) concentrations or to correct the
hypercalcemia
, but it normalized urinary excretion of PGE. Subsequent chemotherapy reduced prostaglandin concentrations toward normal values concomitant with a reduction of clinically estimated
tumor
burden. During this period of time, serum calcium concentrations had no consistent relationship to the plasma PGE levels. We suggest that PGE merely reflected the
tumor
burden of this patient and did not directly contribute to the genesis of her
hypercalcemia
. The pertinent literature relating PGE and
hypercalcemia
is reviewed.
...
PMID:Prostaglandin E and hypercalcemia in breast carcinoma: only a tumor marker? A need for perspective. 21 52
Sixty-eight patients with plasmacytic
neoplasia
and osteosclerotic lesions were analyzed. Men predominated in this series. Mean age was 55.3 years and 26 patients were younger than 51 years at diagnosis. Early onset of disease was statistically different from multiple myeloma in general. Thirty patients had peripheral polyneuropathy and often neurological manifestations preceded other symptoms. Skeletal pain was less common, whereas hepatomegaly, splenomegaly, and lymphadenopathy were more common than in myeloma in general. Incidence of azotemia,
hypercalcemia
, high ESR, and anemia was lower than in myeloma. In one fourth of the patients, the number of skeletal lesions did not exceed three. Mean survival was less than 20 months from first symptom and 12 months from diagnosis. Mortality was related sometimes to polyneuropathy. Thus, in several aspects, plasmacytic
neoplasia
with osteosclerotic lesions is different from the classical multiple myeloma.
...
PMID:Plasma cell neoplasia with osteosclerotic lesions. A study of five cases and a review of the literature. 22 10
A three-month-old girl with nephroblastoma had at the same time a
hypercalcemia
and elevated parathyroid hormone levels. Both biochemical findings disappeared after surgical removal of the
tumor
.
...
PMID:Hypercalcemia and elevated parathyroid hormone levels in association with nephroblastoma. 23 Oct 21
Osteosarcomas were induced in approximately 80% of young New Zealand Black rats by the intratibial inoculation of Moloney murine sarcoma virus from day 1 to day 5 after birth. The neoplasms were composed of a spectrum of well-differentiated to poorly differentiated osteoblasts, osteocytes, and osteoclasts. Budding of C-type viral particles was associated with
tumor
induction. Compared to rats inoculated on day 1 after birth, rats inoculated at 4 days of age developed consistently more osteoproliferative bone tumors that often were associated with
hypercalcemia
, increased serum alkaline phosphatase, and elevated urinary hydroxyproline.
...
PMID:Intratibial Moloney sarcoma virus-induced osteosarcoma in the rat: tumor incidence and pathologic evaluation. 26 94
There is considerable circumstantial evidence to support the concept that prostaglandins of the E series can mediate
hypercalcemia
in
neoplastic disease
. However, other metabolites of prostaglandin endoperoxides could contribute to the
hypercalcemia
and the site of the production of prostaglandins is not established. Further analysis of prostaglandin endoperoxide metabolism in
tumor
and bone tissue and in the circulation will clarify the specific mechanism. The development of quantitative analysis of prostaglandin metabolites had made it possible to identify prostaglandin-dependent
hypercalcemia
. Therapeutic application of the inhibitors of prostaglandin cyclo-oxygenase in the treatment of patients with prostaglandin-mediated
hypercalcemia
is feasible, but its general usefulness remains to be evaluated. The development of antagonists to the action of prostaglandin at the affected end organ site, presumably bone, would represent an important therapeutic advance.
...
PMID:Prostaglandins and hypercalcemic states. 34 34
Malignant neoplasms may cause life-threatening complications requiring prompt diagnosis and emergency therapy. Whether or not the underlying
neoplasm
is potentially curable, the physician can often provide worthwhile prolongation of life and dramatic symptomatic relief. Among the serious complications of
neoplasia
are superior vena cava obstruction, airway obstruction, pericardial tamponade, spinal cord compression, brain metastasis, meningeal involvement by cancer, hyperuricemia,
hypercalcemia
and hyperkalemia.
...
PMID:Emergencies in oncology. Current management. 36 Jun 21
FOR THE PURPOSES OF THIS REVIEW, THE VAST AND INCREASINGLY COMPLEX SUBJECT OF HYPERCALCEMIC DISORDERS CAN BE BROKEN DOWN INTO THE FOLLOWING CATEGORIES: (1) Physiochemical state of calcium in circulation. (2) Pathophysiological basis of
hypercalcemia
. (3) Causes of
hypercalcemia
encountered in clinical practice: causes indicated by experience at the University of California, Los Angeles;
neoplasia
; hyperparathyroidism; nonparathyroid endocrinopathies; pharmacological agents; possible increased sensitivity to vitamin D; miscellaneous causes. (4) Clinical manifestations and diagnostic considerations of hypercalcemic disorders. (5) The management of hypercalcemic disorders: general measures; measures for lowering serum calcium concentration; measures for correcting primary causes-the management of asymptomatic hyperparathyroidism.
...
PMID:The pathophysiology and clinical aspects of hypercalcemic disorders. 36 22
<< Previous
1
2
3
4
5
6
7
8
9
10
Next >>